DDInter1141 DDInter1581
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia although the risk is thought to be lower than that of sulfonylureas since their action is dependent on the presence of glucose. In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control. Meglitinides appear to be more effective at lowering postprandial blood glucose than metformin, sulfonylureas and thiazolidinediones. Repaglinide is extensively metabolized in the liver and excreted in bile. Repaglinide metabolites do not possess appreciable hypoglycemic activity. Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fluoxymesterone
Fluoxymesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Methyltestosterone
Methyltestosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Fluoxymesterone
Fluoxymesterone {u} (Compound) causes {v} (Side Effect) Anaphylactoid reaction
Anaphylactoid reaction {u} (Side Effect) is caused by {v} (Compound) Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} (Compound) binds {v} (Gene) ALB
ALB {u} (Gene) is bound by {v} (Compound) Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Testosterone
Testosterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Difluprednate
Difluprednate {u} (Compound) resembles {v} (Compound) Amcinonide
Amcinonide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Repaglinide
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Dydrogesterone {u} (Compound) resembles {v} (Compound) Fluoxymesterone
Fluoxymesterone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Repaglinide
Megestrol acetate (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Megestrol acetate (Compound) resembles Methyltestosterone (Compound) and Methyltestosterone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Megestrol acetate (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone (Compound) causes Anaphylactoid reaction (Side Effect) and Anaphylactoid reaction (Side Effect) is caused by Repaglinide (Compound)
Megestrol acetate (Compound) resembles Progesterone (Compound) and Progesterone (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Repaglinide (Compound)
Megestrol acetate (Compound) resembles Testosterone (Compound) and Testosterone (Compound) binds ALB (Gene) and ALB (Gene) is bound by Repaglinide (Compound)
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide
Megestrol acetate (Compound) resembles Difluprednate (Compound) and Difluprednate (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Repaglinide
Megestrol acetate (Compound) resembles Dydrogesterone (Compound) and Dydrogesterone (Compound) resembles Fluoxymesterone (Compound) and Fluoxymesterone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide